Award Winner Discusses Potential of Retinal Organoids

Hits:35   Date: 12/17/2025

In a new guest blog post – Dr Owen Jones, winner of the Amsbio 2024 ISSCR Travel Grant, reflects on his work developing and applying human stem cell–derived retinal organoid models for disease research and therapeutic discovery. Amsbio is delighted to have played a supporting role in Dr Jones scientific endeavors.

Dr Owen Jones (Left) with Dr Alex Sim from Amsbio (Right) at ISSCR.

Robust and biologically relevant models are essential for understanding human disease. Millions of people worldwide are affected by retinal disease, many of which remain untreatable and impose a heavy burden on quality of life and healthcare systems. This highlights the urgent need for advanced modelling systems that can inform the development of new therapies.
 

Retinal organoids illustration

In his introduction to retinal organoids, Dr Jones explains how 3D organoids derived from human stem cells overcome the limitations of animal models, which often fail to recapitulate human biology due to species-specific differences, and surpass traditional 2D cultures by capturing the intricacy of multicellular tissue architecture. Retinal organoids mimic key stages of human retinal development, making them highly relevant for studying disease mechanisms.

Dr Jones discusses how retinal organoids offer powerful disease modelling capabilities, are supporting the next wave of therapeutics for treating retinal diseases and the promise of stem cell-derived retinal cell replacement therapies for treating sight loss resulting from retinal degeneration.

To read this informative guest blog in full please visit https://www.amsbio.com/news/retinal_organoids

Amsbio strives to help advance stem cell discovery by supplying research scientists with the necessary tools and reagents needed to work more efficiently and obtain reliable results faster. Stem cells, particularly human embryonic stem cells, are a notoriously labile cell type. Without careful attention, these cells tend to spontaneously differentiate and undergo genomic rearrangements in culture. Today, Amsbio offers researchers an unmatched range of high-performance stem-cell-optimized and qualified growth media, sera, feeder cells, supplements, growth factors, and assay kits.

For further information please contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Now part of the Europa Biosite group of companies, AMS Biotechnology (Amsbio) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. Amsbio has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows Amsbio to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, Amsbio offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, Amsbio is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.
 
---------------------

Worldwide HQ

AMS Biotechnology (Amsbio)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com
Web: www.amsbio.com
 
North American HQ
 
Amsbio LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com
Web: www.amsbio.com